The therapeutic efficacy of resveratrol for acute lung injury-A meta-analysis of preclinical trials

source extracted confidence: high 2026-04-09

The therapeutic efficacy of resveratrol for acute lung injury-A meta-analysis of preclinical trials

Tang et al., 2022 | Front Pharmacol | Systematic Review

Citation

Tang Yin, Fu Wenqiao, ... Tang Wenjing. The therapeutic efficacy of resveratrol for acute lung injury-A meta-analysis of preclinical trials. Front Pharmacol. 2022;13:963245. doi:10.3389/fphar.2022.963245

Abstract

Background: Resveratrol (RES) has a protective effect on acute lung injury (ALI) or acute respiratory distress syndrome (ARDS). Our purpose was to conduct a meta-analysis to investigate the efficacy of RES for ALI/ARDS in animal models. Methods: PubMed, EMBASE and Web of Science were searched to screen relevant preclinical trials. The standardized mean difference (SMD) was used to compare the lung injury score, lung wet-dry weight ratio (W/D ratio), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), IL-6, IL-10, the number of neutrophils in bronchoalveolar lavage fluid (BALF) and the total protein in BALF between the treatment and control groups. SYRCLE's risk of bias tool was used for quality assessment. Results: A total of 17 studies published from 2005 to 2021 were included in our study to calculate the SMD with corresponding confidence interval (CI). As compared with controls, RES significantly decreased the lung injury score (SMD -2.06; 95% CI -2.77, -1.35; p < 0.00001) and W/D ratio (SMD -1.92; 95% CI -2.62, -1.22; p < 0.00001). RES also reduced the number of neutrophils in BALF (SMD -3.03; 95% CI -3.83, -2.24; p < 0.00001) and the total protein in BALF (SMD -5.59; 95% CI -10.10, -1.08; p = 0.02). Furthermore, RES was found to downregulate proinflammatory mediators such as TNF-α (SMD -2.02; 95% CI -3.09, -0.95; p = 0.0002), IL-1β (SMD -2.51; 95% CI -4.00, -1.02; p = 0.001) and IL-6 (SMD -2.26; 95% CI -3.49, -1.04; p = 0.0003). But RES had little effect on the anti-inflammatory mediators such as IL-10 (SMD 2.80; 95% CI -0.04, 5.63; p = 0.05). Sensitivity analysis and stratified analysis were performed for the outcome indicators with heterogeneity. Conclusion: RES treatment is effective on reducing the severity of ALI. However, more animal studies and human trials are needed for further investigation. Our study may provide a reference for preclinical and clinical studies in the future to some extent.

Key Findings

A total of 17 studies published from 2005 to 2021 were included in our study to calculate the SMD with corresponding confidence interval (CI). As compared with controls, RES significantly decreased the lung injury score (SMD -2.06; 95% CI -2.77, -1.35; p < 0.00001) and W/D ratio (SMD -1.92; 95% CI -2.62, -1.22; p < 0.00001). RES also reduced the number of neutrophils in BALF (SMD -3.03; 95% CI -3.83, -2.24; p < 0.00001) and the total protein in BALF (SMD -5.59; 95% CI -10.10, -1.08; p = 0.02). F

Outcomes Measured

  • inflammatory markers

Population

Field Value
Population See abstract
Sample Size 17
Age Range See abstract
Condition stress

MeSH Terms

  • No MeSH terms indexed

Evidence Classification

  • Level: Systematic Review
  • Publication Types: Systematic Review, Journal Article
  • Vertical: resveratrol

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09